PT3902803T - Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro - Google Patents

Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro

Info

Publication number
PT3902803T
PT3902803T PT198457962T PT19845796T PT3902803T PT 3902803 T PT3902803 T PT 3902803T PT 198457962 T PT198457962 T PT 198457962T PT 19845796 T PT19845796 T PT 19845796T PT 3902803 T PT3902803 T PT 3902803T
Authority
PT
Portugal
Prior art keywords
mat2a
aza
cancer
treatment
methods
Prior art date
Application number
PT198457962T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PT3902803T publication Critical patent/PT3902803T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT198457962T 2018-12-27 2019-12-27 Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro PT3902803T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862785519P 2018-12-27 2018-12-27

Publications (1)

Publication Number Publication Date
PT3902803T true PT3902803T (pt) 2023-04-28

Family

ID=69400625

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198457962T PT3902803T (pt) 2018-12-27 2019-12-27 Inibidores aza-heterobicíclicos de mat2a e métodos de utilização para o tratamento do cancro

Country Status (38)

Country Link
US (2) US12077534B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902803B1 (cg-RX-API-DMAC7.html)
JP (3) JP7418441B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250093588A (cg-RX-API-DMAC7.html)
CN (1) CN113454085B (cg-RX-API-DMAC7.html)
AR (1) AR117544A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019416349B2 (cg-RX-API-DMAC7.html)
CA (1) CA3124952C (cg-RX-API-DMAC7.html)
CL (1) CL2021001721A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009879A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210410A (cg-RX-API-DMAC7.html)
DK (1) DK3902803T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191801A1 (cg-RX-API-DMAC7.html)
ES (1) ES2942310T3 (cg-RX-API-DMAC7.html)
FI (1) FI3902803T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20237519B (cg-RX-API-DMAC7.html)
HR (1) HRP20230161T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061834T2 (cg-RX-API-DMAC7.html)
IL (1) IL284326B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210172B1 (cg-RX-API-DMAC7.html)
LT (1) LT3902803T (cg-RX-API-DMAC7.html)
MA (1) MA54608B1 (cg-RX-API-DMAC7.html)
MD (1) MD3902803T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007829A (cg-RX-API-DMAC7.html)
MY (1) MY206578A (cg-RX-API-DMAC7.html)
PE (1) PE20212090A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551490A1 (cg-RX-API-DMAC7.html)
PL (1) PL3902803T3 (cg-RX-API-DMAC7.html)
PT (1) PT3902803T (cg-RX-API-DMAC7.html)
RS (1) RS64135B1 (cg-RX-API-DMAC7.html)
SA (1) SA521422405B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106637SA (cg-RX-API-DMAC7.html)
SI (1) SI3902803T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300109T1 (cg-RX-API-DMAC7.html)
TW (1) TWI816962B (cg-RX-API-DMAC7.html)
UA (1) UA127525C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020139991A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104423B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12503467B2 (en) 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677B (zh) 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
CN115960098B (zh) * 2020-09-11 2026-04-10 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
WO2022143864A1 (zh) * 2020-12-31 2022-07-07 江苏先声药业有限公司 三环类化合物及用途
DE102021102487A1 (de) * 2021-02-03 2022-08-04 Aixinno Limited Verfahren zum Handhaben biologischer Zellkulturen
CN115141202A (zh) * 2021-03-29 2022-10-04 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
JP7721686B2 (ja) * 2021-06-02 2025-08-12 南京正大天晴制薬有限公司 メチオニンアデノシルトランスフェラーゼ2a阻害剤
CN118434722A (zh) 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
MX2024007457A (es) * 2021-12-17 2024-08-27 Tango Therapeutics Inc Formas cristalinas de n-(6-amino-5-metilpiridin-3-il)-2-(benzo[d]t iazol-5-il)-5- metilpiperidin-1-il)-2-oxoacetamida, composiciones farmacéuticas y métodos de uso de estas.
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
CN118742550B (zh) * 2022-03-11 2025-09-05 赛诺哈勃药业(成都)有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
AU2023299635A1 (en) 2022-06-27 2025-01-02 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Tricyclic compounds and uses thereof
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
EP4582423A1 (en) 2022-10-13 2025-07-09 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
CN121241050A (zh) * 2023-03-06 2025-12-30 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
WO2024255802A1 (zh) * 2023-06-14 2024-12-19 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
KR100571339B1 (ko) 2000-08-31 2006-04-17 에프. 호프만-라 로슈 아게 세포증식 억제제로서의 7-옥소 피리도피리미딘
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CA2826034A1 (en) 2011-01-28 2012-08-02 University Of Kentucky Research Foundation Stilbene analogs and methods of treating cancer
WO2016064960A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
UA125852C2 (uk) * 2016-08-31 2022-06-22 Ле Лаборатуар Сервьє Інгібітори клітинних метаболічних процесів
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
HUE066282T2 (hu) 2018-03-30 2024-07-28 Servier Lab Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra
AU2019414446A1 (en) * 2018-12-27 2021-07-15 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
AR119046A1 (es) * 2019-05-31 2021-11-17 Agios Pharmaceuticals Inc Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer

Also Published As

Publication number Publication date
MA54608A (fr) 2022-04-06
KR102823567B1 (ko) 2025-06-20
CA3124952A1 (en) 2020-07-02
SG11202106637SA (en) 2021-07-29
JP2022516883A (ja) 2022-03-03
WO2020139991A1 (en) 2020-07-02
KR20220051301A (ko) 2022-04-26
EP3902803A1 (en) 2021-11-03
RS64135B1 (sr) 2023-05-31
NZ777391A (en) 2025-08-29
UA127525C2 (uk) 2023-09-20
US20220144820A1 (en) 2022-05-12
KR20250093588A (ko) 2025-06-24
FI3902803T3 (fi) 2023-04-25
JOP20210172A1 (ar) 2023-01-30
MA54608B1 (fr) 2023-02-28
JP2024015340A (ja) 2024-02-01
US12077534B2 (en) 2024-09-03
JP2025133887A (ja) 2025-09-11
HUE061834T2 (hu) 2023-08-28
CN113454085A (zh) 2021-09-28
CL2021001721A1 (es) 2022-02-18
CR20210410A (es) 2021-12-08
ES2942310T3 (es) 2023-05-31
TWI816962B (zh) 2023-10-01
MY206578A (en) 2024-12-24
US20250214988A1 (en) 2025-07-03
TW202039490A (zh) 2020-11-01
AU2019416349A1 (en) 2021-07-15
LT3902803T (lt) 2023-04-25
PH12021551490A1 (en) 2022-04-11
SMT202300109T1 (it) 2023-05-12
ZA202104423B (en) 2023-12-20
SA521422405B1 (ar) 2024-04-28
IL284326B2 (en) 2024-08-01
HRP20230161T1 (hr) 2023-04-28
AU2019416349B2 (en) 2023-09-28
BR112021012595A2 (pt) 2021-09-08
IL284326B1 (en) 2024-04-01
GEAP202315703A (en) 2023-02-27
CO2021009879A2 (es) 2021-10-29
EP3902803B1 (en) 2023-02-01
PL3902803T3 (pl) 2023-05-22
AR117544A1 (es) 2021-08-11
MD3902803T2 (ro) 2023-10-31
IL284326A (en) 2021-08-31
JOP20210172B1 (ar) 2024-12-22
JP7418441B2 (ja) 2024-01-19
GEP20237519B (en) 2023-07-10
EA202191801A1 (ru) 2021-11-09
DK3902803T3 (da) 2023-02-13
CN113454085B (zh) 2024-05-07
SI3902803T1 (sl) 2023-06-30
CA3124952C (en) 2024-07-02
PE20212090A1 (es) 2021-11-04
MX2021007829A (es) 2021-10-26

Similar Documents

Publication Publication Date Title
HUE061834T2 (hu) MAT2A aza-heterobiciklusos inhibitorai és alkalmazási eljárások rák kezelésére
IL284324A (en) Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer
HUE066282T2 (hu) Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra
IL272948A (en) ENPP1 inhibitors and their use for cancer treatment
IL272470A (en) Methods and materials for assessing and treating cancer
IL269150A (en) Compositions and methods for treating cancer
IL283149A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
IL268814A (en) Compositions and methods for treatment of cancer
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
IL263224A (en) Methods and compositions for treating cancers
IL282776A (en) Plasmid constructs for treating cancer and methods of use
IL268872A (en) Methods and compositions for treating cancers using antisense
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
IL269157A (en) Compositions and methods for treating cancer
HUE059990T2 (hu) 2-Oxo-tiazol-származékok A2A inhibitorként és a rákos megbetegedések kezelésében alkalmazható vegyületekként
PL3773589T3 (pl) Inhibitor RET do stosowania w leczeniu raka ze zmianą RET
IL282478A (en) Materials and methods for treating cancer
IL288086A (en) Methods and materials for treating cancer
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
IL274198A (en) Use of Nox inhibitors to treat cancer
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
IL282041A (en) Egfr inhibitors for treating keratodermas
IL282948A (en) Compositions and methods for treating cancer
EP3487492A4 (en) USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER